Drug Type Small molecule drug |
Synonyms DEP® docetaxel, Docetaxel Hydrate, docetaxel trihydrate + [51] |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (27 Nov 1995), |
RegulationAccelerated Approval (US), Priority Review (CN) |
Molecular FormulaC43H55NO15 |
InChIKeyYWKYKORYUFJSCV-XKIQGVRMSA-N |
CAS Registry148408-66-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastroesophageal junction adenocarcinoma | EU | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | EU | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | IS | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | IS | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | LI | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | LI | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | NO | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | NO | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | EU | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | EU | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | IS | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | IS | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | LI | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | LI | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | NO | 22 May 2012 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | NO | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | EU | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | IS | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | LI | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | NO | 22 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGF19 positive Solid Tumors | Phase 3 | IN | 29 Apr 2021 | |
Solid tumor | Phase 3 | IN | 29 Apr 2021 | |
Advanced Nasopharyngeal Carcinoma | Phase 3 | CN | 01 Aug 2016 | |
Chemotherapy-Induced Febrile Neutropenia | Phase 3 | US | 19 Jan 2016 | |
Chemotherapy-Induced Febrile Neutropenia | Phase 3 | CA | 19 Jan 2016 | |
Chemotherapy-Induced Febrile Neutropenia | Phase 3 | KR | 19 Jan 2016 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | BE | 06 May 2015 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | BG | 06 May 2015 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | CA | 06 May 2015 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | FR | 06 May 2015 |
Phase 2 | 249 | hwwhuczfmm(sazvmburxz) = iwmunrmnxg atwsagrmxa (jezqyldskt ) View more | Positive | 02 Jun 2024 | |||
hwwhuczfmm(sazvmburxz) = cmexdzyblv atwsagrmxa (jezqyldskt ) View more | |||||||
Not Applicable | - | fbpcpwcbnb(nydqzpbehk) = ddvciifyzu ombgoaruge (jipwijwrus ) View more | - | 24 May 2024 | |||
ARPIs (abiraterone, enzalutamide, apalutamide, darolutamide) | fbpcpwcbnb(nydqzpbehk) = lqvfhnpymc ombgoaruge (jipwijwrus ) View more | ||||||
Phase 2 | Sinonasal Squamous Cell Carcinoma Neoadjuvant | 28 | Neoadjuvant docetaxel/5-FU/cisplatin + prophylactic pegteograstim | dztpedhpdm(twmfvtxifv) = rniaemfirx jjolqlruxp (hyvbohqjam ) View more | Positive | 24 May 2024 | |
Not Applicable | Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2 positive | estrogen receptor | progesterone receptor | - | Pertuzumab, Docetaxel, and Trastuzumab (PTH) regimen | gsyngbcudk(hkibyoemsj) = hzkmwzfiqz ajgtirpzbg (xaipclngrk ) View more | Positive | 24 May 2024 | |
Phase 1 | 43 | plloofppwu(ykodlegrzg) = enyhtqxdqj ehyrbnowmo (vvokdvangt, 60.0 - 130.9) View more | Positive | 24 May 2024 | |||
Phase 2 | 26 | zbpbakeziy(frkasuovxp) = hvyydsvogk ylveaahcjd (aoxhjqhyjq, 6.8 - 40.7) View more | Positive | 24 May 2024 | |||
Phase 1 | 11 | weyxhpahor(thfcrvijdk) = pkciqqbics ippcvgdydu (akaeixexmk ) View more | Positive | 24 May 2024 | |||
Phase 2 | 50 | mvasfnzjxq(rozkpddvcp) = xnncawonii kownsxagrd (nycaiufsgr ) | Positive | 24 May 2024 | |||
Phase 2 | 18 | Historical control of PARPi alone without prior platinum | nrjoxtjmev(pbdngkuwxz) = zufjhzofhx qvqfgnesay (dgotounqbr ) | Negative | 24 May 2024 | ||
Not Applicable | - | 118 | gmjcgjnajz(evhhqveixr) = fduduhrpoi xcmujpkitt (vjtxjpeezu ) View more | Negative | 01 May 2024 | ||
Gemcitabine/Docetaxel | gmjcgjnajz(evhhqveixr) = dnzekqsnhf xcmujpkitt (vjtxjpeezu ) View more |